Last updated: February 20, 2026
What is the drug associated with NDC 62135-0438?
NDC 62135-0438 is linked to Leqvio (inclisiran). It is a lipid-lowering therapy used to reduce LDL cholesterol in patients with cardiovascular disease or familial hypercholesterolemia.
Market Overview
Leqvio (inclisiran) is a subcutaneous small interfering RNA (siRNA) agent developed by Novartis. It targets PCSK9 mRNA to lower LDL cholesterol levels efficiently. Launched in the U.S. in late 2021, it addresses an unmet need in chronic lipid management.
Commercial and Clinical Adoption
- Market penetration remains gradual, driven by physicians' familiarity with novel biologics and patient preferences.
- Pricing and reimbursement are barriers; coverage varies among commercial insurers, Medicare, and Medicaid.
- Competitors include other LDL-lowering agents like PCSK9 inhibitors (Repatha, Praluent) and statins.
Patient Population
- Estimated 4.4 million adults in the U.S. with high cholesterol suitable for PCSK9 inhibitors.
- Patients prescribed inclisiran tend to have statin intolerance or require additional LDL reduction.
Market Size and Revenue Projections
Current Market Size
- In 2022, the U.S. market for PCSK9 inhibitors was approximately $2.5 billion.
- Inclisiran's share accounts for roughly 10% of the PCSK9 class, valued at about $250 million.
- Worldwide sales are expected to reach $450 million to $600 million in 2023.
Revenue Growth Drivers
- Pricing strategy: Inclisiran's list price is approximately $3,200 per dose, with dosages administered at baseline, 3 months, then every 6 months.
- Reimbursement challenges reduce net sales; average net price can be 20-30% lower.
- Market expansion beyond the U.S. into Europe and other global regions may increase revenue.
Market Penetration Forecasts
| Year |
Estimated Revenue (USD) |
Notes |
| 2023 |
$400 million – $600 million |
Market expansion, increased provider adoption |
| 2024 |
$700 million – $900 million |
Higher penetration, broader insurance coverage |
| 2025 |
$1.2 billion – $1.5 billion |
Arrival of generics for competitors, increased uptake |
Price Projections
- List Price: Expected to remain stable around $3,200 per dose through 2025.
- Net Price: Will decline by 10-20% annually as rebates and discounts increase.
- Global Pricing Trends: European markets could see prices 10-15% lower due to payer negotiations.
Competitive Landscape and Pricing Dynamics
Key Competitors
- Repatha (evolocumab) and Praluent (alirocumab) are established PCSK9 inhibitors with annual treatments costing $6,000–$7,000.
- Inclisiran offers biannual dosing, which may improve adherence but generally has lower per-dose revenue due to pricing.
Regulatory Influences
- Insurance reimbursement policies affect net revenue.
- Pricing pressure from payers seeking discounts on biologics is likely to persist.
Market Risks and Opportunities
Risks
- Entry of biosimilars or generics may lower prices.
- Slow adoption amid clinician hesitance or lack of awareness.
- Potential regulatory or policy changes impacting drug reimbursement.
Opportunities
- Expanding indications, such as in pediatrics or other lipid disorders.
- Leveraging post-marketing studies to demonstrate long-term benefits.
- Broadening geographic reach, notably in Asia-Pacific and Latin America.
Summary
Inclisiran (NDC 62135-0438) is a late-stage cholesterol-lowering biologic with a steadily growing market that could reach $1 billion in 2024. Its price point remains around $3,200 per dose, with net prices declining due to payer negotiations. The drug’s success depends on market penetration, reimbursement dynamics, and competitive positioning against existing PCSK9 inhibitors.
Key Takeaways
- The U.S. market for inclisiran is projected to surpass $900 million by 2024.
- List price is stable, but net revenue per dose declines over time.
- Physician adoption is critical; awareness campaigns and clinical data influence uptake.
- Competition from established PCSK9 inhibitors constrains pricing power.
- International expansion remains a significant growth opportunity.
FAQs
Q1: What factors most influence inclisiran’s market penetration?
A1: Physician awareness, insurance reimbursement, patient acceptance, and comparative efficacy data.
Q2: How does inclisiran’s dosing schedule impact its market position?
A2: Biannual dosing improves adherence and patient convenience, providing a competitive advantage over monthly injections.
Q3: What are the key pricing considerations for inclisiran?
A3: Maintaining a competitive list price while negotiating favorable rebates and insurance coverage.
Q4: How might biosimilars affect inclisiran’s pricing?
A4: Biosimilar entry could reduce prices and net revenues, particularly after patent expiry, approximately in 2035.
Q5: What are the main international markets for inclisiran?
A5: Europe is the primary international market, with emerging opportunities in Latin America and Asia-Pacific regions.
References
- IQVIA. (2023). Pharmaceutical Market Reports.
- Novartis. (2022). Leqvio (inclisiran) Prescribing Information.
- EvaluatePharma. (2023). World Market for PCSK9 Inhibitors.
- CMS. (2022). Medicare Reimbursement Policies for Biologics.
- FDA. (2021). Inclisiran Approval Summary.
